Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jul 17;41(1):49-61.
doi: 10.1016/j.immuni.2014.06.010.

Tumor-associated macrophages: from mechanisms to therapy

Roy Noy  1 , Jeffrey W Pollard  2
Affiliations
Review

Tumor-associated macrophages: from mechanisms to therapy

Roy Noy et al. Immunity. .

Erratum in

  • Immunity. 2014 Nov 20;41(5):866

Abstract

The tumor microenvironment is a complex ecology of cells that evolves with and provides support to tumor cells during the transition to malignancy. Among the innate and adaptive immune cells recruited to the tumor site, macrophages are particularly abundant and are present at all stages of tumor progression. Clinical studies and experimental mouse models indicate that these macrophages generally play a protumoral role. In the primary tumor, macrophages can stimulate angiogenesis and enhance tumor cell invasion, motility, and intravasation. During monocytes and/or metastasis, macrophages prime the premetastatic site and promote tumor cell extravasation, survival, and persistent growth. Macrophages are also immunosuppressive, preventing tumor cell attack by natural killer and T cells during tumor progression and after recovery from chemo- or immunotherapy. Therapeutic success in targeting these protumoral roles in preclinical models and in early clinical trials suggests that macrophages are attractive targets as part of combination therapy in cancer treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Tumor-associated macrophages in the primary tumor promote malignancy
In the primary tumor microenvironment macrophages under the influence of IL-4 produced by CD4+ T cells and tumors and WNT7b promote tumor cell invasion. This invasion is mediated via a paracrine loop involving tumor-synthesized CSF1 and macrophage-produced EGF that drives migration of tumor cells in lock-step with macrophages along collagen fibres that act as highways towards blood vessels. This process also requires TGFβ that drives n epithelial-mesenchymal transition (EMT) in the tumor cells that promotes migration and matrix remodelling via Cathepsins and matrix adhesion of tumor cells via SPARC. This streaming of tumor cells results in their pileup on the vessels where macrophages promote their intravasation into the circulation through a structure named the “Tumor Microenvironment of Metastasis” (TMEN). In addition to effect on tumor cell migration and invasion TIE2+ macrophages produce VEGF and WNT7b that stimulates angiogenesis in the tumor. Thus there is an additive effect caused by macrophages of increased migration of tumor cells towards vessels and increased vascular targets that results in a large number of circulating tumor cells and thus increased malignancy. Macrophages also suppress cytotoxic T-cell responses through the mechanisms described in figure 2.
Figure 2
Figure 2. Pro-tumor macrophage mechanisms of effector cells inhibition
TAMs express an array of effector molecules that inhibit the anti-tumor immune responses; this includes cell surface receptors, cytokines, chemokines and enzymes. Inhibition of immune responses by direct cell-to cell-contact is based on the interaction of TAMs receptors ligands with their counterpart death/inhibitory receptors expressed by the target immune effector cells. TAMs express the ligand receptors for PD-1 and CTLA-4 that upon activation suppress cytotoxic functions of T- cell, NKT cells and NK cells. TAMs also express the ligand for the death receptors FAS and TRAIL that triggers in target cells caspase dependent cell death (apoptosis). TAMs also express the non-classical HLA-G that inhibits T cell function through interaction with the co-stimulatory signal of T cells ILT2, and HLA-E that inhibit NK cells through CD94 (also known as NKG2). TAMs secrete the cytokines IL-10 and TGFβ that inhibit T cells effector functions and induce regulatory functions, and chemokines CCL5, CCL20, CCL22 that recruit nTreg cells. TAMs secrete Arginase I that inhibit TCR ζ chain re-expression in activated T cells by the depletion of L-arginine.
Figure 3
Figure 3. Macrophages promote metastasis
Arrest of tumor cells in the vasculature of target organs through the formation of microclots (1) results in CCL2-mediated recruitment of CCR2-expressing circulating inflammatory monocytes (2). These monocytes differentiate into metastasis-associated macrophages (MAMs) that mediate tumor cell extravasation via VEGF that increases vascular permeability (3). MAMS under the influence of CSF-1 further promote tumor cell survival (4) and persistent growth associated by angiogenesis and may also prevent T cell cytotoxicity (5).
Figure 4
Figure 4. Re-programming Macrophages to be Anti-Tumoral
Macrophages in the tumor in general are immunoregulatory and suppress immune responses to tumor-derived antigens. However, in some circumstances particularly with appropriate therapeutic interventions, macrophages can be anti-tumoral by direct tumor cell killing, the removal of vital support such as inhibition of angiogenesis or by the activation T cells. This differential polarization is under the control of many stimuli as shown that alters the differentiated state of the macrophages. Some factors such as GM-CSF act in pro- or anti-tumoral fashion dependent on context (Pyonteck et al., 2013; Su et al., 2014). Therapeutic interventions can re-polarize these cells to become immunostimulatory macrophages that on their own can cause tumor regression or that enhance the activity of chemo-, anti-vascular or immuno-therapies. References to these polarizing agents can be found in (De Palma and Lewis, 2013; Sica and Mantovani, 2012).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abraham D, Zins K, Sioud M, Lucas T, Schafer R, Stanley ER, Aharinejad S. Stromal cell-derived CSF-1 blockade prolongs xenograft survival of CSF-1-negative neuroblastoma. Int. J. Cancer. 2010;126:1339–1352. - PMC - PubMed
    1. Adeegbe DO, Nishikawa H. Natural and induced T regulatory cells in cancer. Frontiers in immunology. 2013;4:190. - PMC - PubMed
    1. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer cell. 2005;7:211–217. - PubMed
    1. Balkwill FR, Mantovani A. Cancer-related inflammation: common themes and therapeutic opportunities. Semin. Cancer Biol. 2012;22:33–40. - PubMed
    1. Belai EB, de Oliveira CE, Gasparoto TH, Ramos RN, Torres SA, Garlet GP, Cavassani KA, Silva JS, Campanelli AP. PD-1 blockage delays murine squamous cell carcinoma development. Carcinogenesis. 2014;35:424–431. - PubMed

Publication types